Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Let's see if Novartis (NVS) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Consider Novartis (NVS) Stock Now?

Blackrock Inc

Bank of Nova Scotia

Cummins

Lowe's

Merck

PPG Industries

Stanley Black & Decker

V.F.

The 2022 correction is frustrating many investors who have been spoiled by years of Buffett-like returns with almost no volatility.

9 No-Brainer Dividend Blue-Chips For A Rich Retirement

Molecular Partners AG

Molecular Partners AG MOLN and its partner Novartis AG NVS, have requested FDA Emergency Use Authorization (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19

With the proceeds from the sale of its Roche shares and its strong Free Cash Flow, Novartis AG repaid $23.6B of its debt in FY2021. Despite developing the world's most expensive drug, Zolgensma, NVS has not reported rewarding revenues from its Spinal Muscular Atrophy therapeutics.

Cash Rich Novartis AG Paid Off $23.6B Of Its Net Debt In FY2021

Contrarian idea after the Q4 results. Solid Q4 results.

Novartis: A Good Long-Term Pick

Novartis AG (NVS) CEO Vasant Narasimhan on Q4 2021 Results - Earnings Call Transcript

Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.

Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing

Novartis AG NVS reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year, benefiting from the sale of its stake in Roche Holding AG RHHBY. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues

Novartis is a large cap pharma company from Switzerland with a portfolio that is broadly diversified both in terms of products and in terms of geography.

Novartis - No Need To Rush Buying This Broadly Diversified Swiss Quality Business

Novartis says its Sandoz generics unit has received interest from private equity.

Novartis Earnings Rise, Says Review of Sandoz Unit Progressing

Novartis reported fourth-quarter core operating income gained 9% as higher drug sales offset in increase in marketing and development costs.

Novartis Q4 core operating income gains 9%

Ad hoc announcement pursuant to Art. 53 LR

Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021

How to spend $45 billion is a nice problem to have. That's the sum Swiss pharmaceutical giant Novartis AG ( NVS , Financial) will have at its disposal if a rumored sale of its Sandoz unit materializes.

Sale Rumors of Novartis' Sandoz Unit Are Heating Up

Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Novartis AG's unit NVS Sandoz, Bloomberg reports, citing people close to the matter.  Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report

Blackstone Group

Private equity firms Blackstone Inc and Carlyle Group Inc are in talks about potentially teaming up on a bid for Swiss drugmaker Novartis' generics unit, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.

Blackstone, Carlyle consider joint bid for Novartis generics unit - Bloomberg News

AbbVie

Humana

Marathon Petroleum

U.S. equity markets opened mixed on Monday, with the Dow Jones industrials lagging and the tech-heavy Nasdaq adding about 1.5% in the early going.

Earnings Previews: AbbVie, Humana, Marathon Petroleum, Novartis

Atmos Energy

Johnson & Johnson

Altria

Northwest Natural Gas

Reckitt Benckiser Group PLC

RenaissanceRe Hlds

Unilever

Verizon

Volatility is back on Wall Street, with tech suffering its worst month since 2008. No one knows how long or deep the 2022 correction will be, but prudent risk-management, not market timing is your best option for protecting your retirement nest egg.

10 High-Yield Sleep Well At Night Blue-Chips Perfect For This Correction

This company's business is built to weather almost any storm.

1 Top Dividend Stock to Buy Right Now

Chevron

Both of these businesses could also be good growth plays.

2 Cheap Dividend Stocks With Yields Above 3%

Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.

Novartis Hopes to Have Another COVID Therapy on the Way

GlaxoSmithKline

Surface Oncology Inc

SURF is an early-stage cancer therapeutics company with multiple big pharma partnerships.

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Applied Materials

Coinbase

Intel

Pfizer

StoneCo

These seven long-term stocks are among the best picks for truly long-term investors looking for companies to hold for the next decade. The post 7 Best Long-Term Stocks to Buy and Hold for the Next Decade appeared first on InvestorPlace.

7 Best Long-Term Stocks to Buy and Hold for the Next Decade

Molecular (MOLN) and Novartis announce encouraging data from a phase II study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19. Shares of Molecular Partners gain on the same.

Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug

After getting positive trial data, Novartis AG (NYSE: NVS) said it would in-license a new drug developing with Molecular Partners AG (NASDAQ: MOLN) to treat COVID-19. Novartis will pay CHF 150 million to in-license ensovibep from Molecular Partners.

Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data

Novartis says it will license antiviral Covid-19 treatment ensovibep from Molecular Partners following positive trial results.

Molecular Partners Stock Surges as Novartis Plans to License Covid-19 Drug

News for Novartis Stock (NVS)